Too many promises and too many delays. Agreed! And we should...

Too many promises and too many delays. Agreed! And we should expect that to continue. Let's call it a "feature" of the company.
I have lowered my expectations to:
- no tangible progress in the Zeiss development in this half year (i.e. no completion of final studies, no real progress on FDA approval) and
- no booked revenue through MR solutions this quarter.
However I do believe the MR solutions product will get on stream within months, before Optiscan runs out of money, and so will tide the company over till the Zeiss product starts selling. I am confident the company will survive............................... to thrive in the future - I hope.